Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for Anxiety in Youth With Autism Spectrum Disorders
NCT01395953Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder comparing Buspirone with Placebo (2 arms). Primary endpoints: Pediatric Anxiety Rating Scale at 8 weeks and Clinical Global Impression-Anxiety Improvement at 8 weeks. Planned start Nov 2011; status: withdrawn.
02
Drugs
buspirone
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT01395953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395953.